Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PARN | O95453 | 1/20 | 0.33 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9197448 | 0.82 | GDA (0.57) | GDAPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL5512566 | 0.79 | GDA (0.57) | GDAPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL9161807 | 0.79 | GDA (0.57) | GDAPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL9194843 | 0.79 | GDA (0.62) | GDAADORA2BPDE4AADORA2APDE4B | |
| SCHEMBL1065848 | 0.78 | GDA (0.53) | GDAADORA2BALDH1A1PARNCNOT7 | |
| SCHEMBL10408058 | 0.77 | GDA (0.55) | GDAPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL1460591 | 0.76 | GDA (0.63) | GDAADORA2BPDE4AADORA2APDE4B | |
| SCHEMBL9302134 | 0.76 | ADORA2B (0.56) | ADORA2BPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL9386098 | 0.75 | GDA (0.57) | GDAPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL11471010 | 0.75 | GDA (0.57) | GDAPDE4AADORA2APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272897-B1 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | UNIV NEW YORK (US) | 2008-05-07 | — | — | EP | claimed |
| US-6555545-B2 | Adenosine, caffeine, and 8-styryl-1,3,7-alkyl xanthine derivatives as wound healing agents | NEW YORK UNIVERSITY | 2003-04-29 | — | — | US | claimed |
| EP-1272897-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | NEW YORK UNIVERSITY (US) | 2003-01-08 | — | — | EP | claimed |
| WO-2001058241-A9 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | UNIV NEW YORK (US) | 2002-10-17 | — | — | WO | claimed |
| US-20020002145-A1 | Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver | NEW YORK UNIVERSITY | 2002-01-03 | — | — | US | claimed |
| WO-2001058241-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | NEW YORK UNIVERSITY (US) | 2001-08-16 | — | — | WO | claimed |
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2025-01-30 | — | — | US | disclosed |
| US-11958854-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3251675-B1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | SHANTON PHARMA PTE LTD (SG) | 2021-04-21 | — | — | EP | disclosed |
| WO-2006045565-A1 | XANTHINE DERIVATIVES WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-04 | — | — | WO | disclosed |
| WO-2005077950-A2 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| US-6555545-B2 | Adenosine, caffeine, and 8-styryl-1,3,7-alkyl xanthine derivatives as wound healing agents | NEW YORK UNIVERSITY | 2003-04-29 | — | — | US | disclosed |
| EP-1272897-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | NEW YORK UNIVERSITY (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001058241-A9 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | UNIV NEW YORK (US) | 2002-10-17 | — | — | WO | disclosed |
| US-20020002145-A1 | Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver | NEW YORK UNIVERSITY | 2002-01-03 | — | — | US | disclosed |
| WO-2001058241-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | NEW YORK UNIVERSITY (US) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002145-A1 | Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver | ADORA2A, ADORA1, ADORA2B | GDA 273/4885ADORA2B 3/4885PDE4A 80/4885 |
| US-11958854-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | GDA 1004/4885ADORA2B 577/4885PDE4A 615/4885 |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | GDA 1004/4885ADORA2B 577/4885PDE4A 615/4885 |
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | GDA 1004/4885ADORA2B 577/4885PDE4A 615/4885 |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | GDA 1004/4885ADORA2B 577/4885PDE4A 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.